Novo Nordisk A/S
Novo Nordisk is a global healthcare company dedicated to defeating diabetes and other serious chronic diseases. The company focuses on research, development, and manufacturing of medicines, with a strong emphasis on sustainability, innovation, and corporate governance. It is committed to long-term success by creating shared value for society and investors, guided by its values and the Novo Nordisk Way.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele
US-12600773-B2
View DetailsInjection device for delivering a predefined plurality of predetermined dose volumes
US-12558493-B2
View Details
Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele
US-12600773-B2
View DetailsInjection device for delivering a predefined plurality of predetermined dose volumes
US-12558493-B2
View DetailsProducts
R&D pipeline (portfolio of therapeutics in development)
A portfolio of discovery and development-stage therapeutic assets focused on chronic diseases and rare conditions.
R&D pipeline (portfolio of therapeutics in development)
A portfolio of discovery and development-stage therapeutic assets focused on chronic diseases and rare conditions.
Services
Program to share compounds and collaborate with external research partners for preclinical research and early development.
Country-specific online portals providing product and disease resources for healthcare professionals.
Channels for patients and healthcare professionals to report side effects and product issues for investigation.
Global platform to support clinical trial operations, site identification and participant recruitment.
Localized contact points for patient inquiries, product availability and usage guidance.
Program to share compounds and collaborate with external research partners for preclinical research and early development.
Country-specific online portals providing product and disease resources for healthcare professionals.
Channels for patients and healthcare professionals to report side effects and product issues for investigation.
Global platform to support clinical trial operations, site identification and participant recruitment.
Localized contact points for patient inquiries, product availability and usage guidance.
Expertise Areas
- Clinical trial management
- Regulatory affairs and submissions (European focus)
- Pharmacovigilance and safety surveillance
- Drug discovery and translational research
Key Technologies
- Phase III clinical trial execution
- Regulatory dossier preparation and submission (EMA)
- Pharmacovigilance/adverse event reporting systems
- Digital portals for healthcare professionals
News & Updates
On June 12, 2025, Novo Nordisk announced the advancement of their weight management drugs into phase 3 clinical trials.
On June 10, 2025, Novo Nordisk presented new data at ADA 2025, showcasing their innovative treatments for obesity and diabetes.
On May 16, 2025, it was announced that Lars Fruergaard Jørgensen will step down as CEO.
On June 12, 2025, Novo Nordisk announced the advancement of their weight management drugs into phase 3 clinical trials.
On June 10, 2025, Novo Nordisk presented new data at ADA 2025, showcasing their innovative treatments for obesity and diabetes.
On May 16, 2025, it was announced that Lars Fruergaard Jørgensen will step down as CEO.